Marcos Blancarte Ibarra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marcos Blancarte Ibarra has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Cristhiam Mauricio Rojas Hernandez
Section of Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, USA
1 shared publication - Elysa Cortez
The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, United States
1 shared publication - Erick Torres Luna
Instituto Tecnologico de Monterrey, Monterrey, NL, Mexico
1 shared publication Herney A Garcia-Perdomo
Division of Urology/Urooncology, Department of Surgery, School of Medicine, . Universidad del Valle. Cali, Colombia
1 shared publicationImelda E Riojas Suárez
Universidad de Monterrey, Monterrey, NL, Mexico
1 shared publication
Latest Publications
- Open Access
- 11 July 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (8)
Risk of venous thromboembolism with CDK 4/6 inhibitor use in breast cancer: A systematic review and meta-analysis.
Hormone receptor-positive (HR+), HER2 negative, non-metastatic breast cancer represents a significant proportion of early-stage breast cancer. The introduction of cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors combined with endocrine therapy (ET), have significantly improved disease free survival. Existing studies suggest that CDK 4/6 inhibitors are associated with an increased risk of venous thromboembolism (VTE). We further studied this risk. The databases Medline, Embase, and Cochrane Central Register of Controlled Trials (Central) were searched. 4,624 publications were screened for inclusion, and seven studies were selected for data extraction and analysis. Publications included studied patients who had a diagnosis of non-metastatic breast cancer and received treatment with CKD 4/6 inhibitors. Major exclusion criteria included age <18 years-old, metastatic cancer, and patients already diagnosed with a hypercoagulable disorder. The statistical analysis was performed using RevMan 9.19.0. We reported information in Risk Ratio (RR) and pooled the information with a random-effect meta-analysis according to the heterogeneity expected. We observed the incidence of VTE in the group of patients treated with CDK 4/6 inhibitors to be larger (68/3165) than the incidence of VTE in patients treated with ET alone (11/2205). We found the relative risk of developing VTE was significantly higher with CDK 4/6 inhibitor treatment than with treatment with ET alone (RR 3.8, 95% CI 2.0 to 7.2). Overall, there was not a significant variability in effect estimates from the included studies (I2=0%). As the use of CDK 4/6 grows, this information will help conversations about risks and benefits when selecting treatment plans.
- 11 July 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (8)
Open AccessRisk of venous thromboembolism with CDK 4/6 inhibitor use in breast cancer: A systematic review and meta-analysis.
Hormone receptor-positive (HR+), HER2 negative, non-metastatic breast cancer represents a significant proportion of early-stage breast cancer. The introduction of cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors combined with endocrine therapy (ET), have significantly improved disease free survival. Existing studies suggest that CDK 4/6 inhibitors are associated with an increased risk of venous thromboembolism (VTE). We further studied this risk. The databases Medline, Embase, and Cochrane Central Register of Controlled Trials (Central) were searched. 4,624 publications were screened for inclusion, and seven studies were selected for data extraction and analysis. Publications included studied patients who had a diagnosis of non-metastatic breast cancer and received treatment with CKD 4/6 inhibitors. Major exclusion criteria included age <18 years-old, metastatic cancer, and patients already diagnosed with a hypercoagulable disorder. The statistical analysis was performed using RevMan 9.19.0. We reported information in Risk Ratio (RR) and pooled the information with a random-effect meta-analysis according to the heterogeneity expected. We observed the incidence of VTE in the group of patients treated with CDK 4/6 inhibitors to be larger (68/3165) than the incidence of VTE in patients treated with ET alone (11/2205). We found the relative risk of developing VTE was significantly higher with CDK 4/6 inhibitor treatment than with treatment with ET alone (RR 3.8, 95% CI 2.0 to 7.2). Overall, there was not a significant variability in effect estimates from the included studies (I2=0%). As the use of CDK 4/6 grows, this information will help conversations about risks and benefits when selecting treatment plans.